ATE282707T1 - Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung - Google Patents

Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung

Info

Publication number
ATE282707T1
ATE282707T1 AT97950737T AT97950737T ATE282707T1 AT E282707 T1 ATE282707 T1 AT E282707T1 AT 97950737 T AT97950737 T AT 97950737T AT 97950737 T AT97950737 T AT 97950737T AT E282707 T1 ATE282707 T1 AT E282707T1
Authority
AT
Austria
Prior art keywords
linker
nucleic acid
vectors
expression
flanking region
Prior art date
Application number
AT97950737T
Other languages
English (en)
Inventor
Michael Coleman
Robert Schwartz
Francesco J Demayo
Original Assignee
Valentis Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc, Baylor College Medicine filed Critical Valentis Inc
Application granted granted Critical
Publication of ATE282707T1 publication Critical patent/ATE282707T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97950737T 1996-12-02 1997-12-01 Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung ATE282707T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3153996P 1996-12-02 1996-12-02
US97457297A 1997-11-19 1997-11-19
PCT/US1997/021852 WO1998024922A1 (en) 1996-12-02 1997-12-01 Insulin-like growth factor i (igf-i) expression system and methods of use

Publications (1)

Publication Number Publication Date
ATE282707T1 true ATE282707T1 (de) 2004-12-15

Family

ID=26707375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950737T ATE282707T1 (de) 1996-12-02 1997-12-01 Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung

Country Status (7)

Country Link
US (1) US20030018984A1 (de)
EP (1) EP0943003B1 (de)
JP (1) JP4131569B2 (de)
AT (1) ATE282707T1 (de)
CA (1) CA2274314C (de)
DE (1) DE69731660T2 (de)
WO (1) WO1998024922A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297375A1 (en) 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
US6723707B1 (en) * 1997-08-25 2004-04-20 The Trustees Of The University Of Pennsylvania Use of insulin-like growth factor-I in muscle
EP1115857A1 (de) * 1998-09-25 2001-07-18 Aventis Pharma S.A. Benutzung von spezifischen hybridpromotoren zur kontrolle der gewebeexpression
FR2783839B1 (fr) * 1998-09-25 2002-12-06 Aventis Pharma Sa Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
US6924365B1 (en) * 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
ES2156769B1 (es) * 1999-11-26 2002-03-01 Univ Barcelona Autonoma Gen quimerico que permite expresar el gen o el cdna del factor de crecimiento similar a la insulina de tipo i (igf-i) en pancreas y su utilizacion para la terapia genica de la diabetes mellitus.
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
US7326417B2 (en) 2001-09-11 2008-02-05 Merial Ltd. IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
FR2829498B1 (fr) * 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2004081040A2 (en) * 2003-03-12 2004-09-23 Advisys, Inc. Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
CN102978202A (zh) * 2012-10-10 2013-03-20 中国农业科学院北京畜牧兽医研究所 一种肌肉特异表达猪igf1基因的过表达载体
KR20260085174A (ko) 2016-10-11 2026-06-08 파마 싱크, 엘엘씨 짧은 형태의 간상체 유래 원추체 생존능 인자와 친수성 펩타이드 사이의 융합 단백질
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
JP7380670B2 (ja) * 2018-07-17 2023-11-15 ヘリックスミス カンパニー， リミテッド Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療
CA3106078A1 (en) * 2018-07-17 2020-01-23 Junghun Lee Treatment of neuropathy with dna constructs expressing igf-1 isoforms
CN112770776B (zh) * 2018-07-30 2025-08-19 瑞德库尔有限责任公司 用于样品处理或分析的方法和系统
WO2020076976A1 (en) 2018-10-10 2020-04-16 Readcoor, Inc. Three-dimensional spatial molecular indexing
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするｒｎａ
WO2021155063A1 (en) 2020-01-29 2021-08-05 Readcoor, Llc Compositions and methods for analyte detection
US20220049303A1 (en) 2020-08-17 2022-02-17 Readcoor, Llc Methods and systems for spatial mapping of genetic variants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use

Also Published As

Publication number Publication date
CA2274314C (en) 2007-03-13
DE69731660D1 (de) 2004-12-23
CA2274314A1 (en) 1998-06-11
WO1998024922A1 (en) 1998-06-11
JP2001505435A (ja) 2001-04-24
EP0943003A1 (de) 1999-09-22
DE69731660T2 (de) 2005-12-22
US20030018984A1 (en) 2003-01-23
EP0943003B1 (de) 2004-11-17
JP4131569B2 (ja) 2008-08-13

Similar Documents

Publication Publication Date Title
DE69731660D1 (de) Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung
US6919208B2 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
HU9500870D0 (en) Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
NZ291689A (en) Peptide of 145 to 167 amino acids capable of modulating body weight in mammals
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
PL331005A1 (en) Regulating dna of hamster's ef-1alpha transcription
AU7833494A (en) Enhanced expression in plants using non-translated leader sequences
ATE438414T1 (de) Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
ATE329030T1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
WO1998046781A3 (en) Novel transgene expression system for increased persistence
AU7891498A (en) Flower organ-specific gene and its promoter sequence
MXPA04003944A (es) Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
EP1008351A4 (de) Karzinostatische wirkstoffe
AU8435698A (en) Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
NZ332897A (en) Methods and compositions for modulating production of a T helper type 2 (Th2)-associated cytokine by regulating transcription factor activity in association with a Nuclear Factor of Activated T cells (NF-AT) protein
WO2004033653A3 (en) Gene regulation with aptamer and modulator complexes for gene therapy
PL313445A1 (en) Grb3-3 gene, variants thereof and their use
DE69637041D1 (de) Dna-fragment, dieses enthaltender rekombinanter vektor und verfahren zur expression von fremdgenen unter dessen verwendung
Oida et al. Cloning and sequence of bone morphogenetic protein 4 (BMP-4) from a human placental cDNA library
EP0763205A4 (de) Nukleinsäuresequenzen die lungenzellenspezifishe genexpression kontrollieren
HUT65492A (en) Biosynthetic process for the preparation of dedydro-amino acid-remainds and tioether-bridge contaning chemical compounds
DE60028217D1 (de) Zyklische depsipeptid-synthasen, deren gene und system zur massenproduktion von zyklischen depsipeptiden
JPS5756495A (en) Novel dna-introduction vector and recombinant dna
WO2001082973A3 (en) Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties